- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07583563
An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly
A Multi-Center, Multinational, Observational Study of Octreotide Subcutaneous Depot for the Treatment of Patients With Acromegaly
The purpose of this study is to collect long-term (up to two years) safety and effectiveness of octreotide subcutaneous depot in patients with acromegaly in the real-world setting.
연구 개요
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Camurus AB
- 전화번호: +46 46 286 57 30
- 이메일: medicalinfo@camurus.com
연구 장소
-
-
-
Aachen, 독일, 52074
- 모병
- Universitaetsklinikum Aachen
-
Leipzig, 독일, 04103
- 모병
- Universitaetsklinikum Leipzig
-
Magdeburg, 독일, 39110
- 모병
- Fachpraxis für Innere Medizin, Endokrinologie und Diabetologie
-
München, 독일, 81667
- 아직 모집하지 않음
- Medicover Neuroendokrinologie MVZ
-
Münster, 독일, 48149
- 아직 모집하지 않음
- Universitätsklinikum Münster
-
Würzburg, 독일, 97080
- 모병
- Universitätsklinikum Würzburg
-
-
-
-
-
Leeds, 영국, LS9 7TF
- 아직 모집하지 않음
- St James's University Hospital - Leeds Teaching Hospitals NHS Trust
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
The study will enroll patients with acromegaly who are considered for treatment with octreotide subcutaneous depot and patients with acromegaly who have already initiated octreotide subcutaneous depot treatment. The study will be conducted in Germany, the UK, and the US.
설명
Inclusion Criteria:
- Have started or will be starting treatment with octreotide SC depot for acromegaly
Exclusion Criteria:
- Have started or will be starting treatment with octreotide SC depot for other conditions not related to acromegaly
- Currently taking part in an interventional clinical trial or is still within a 30-day washout period from the end of taking part in an interventional clinical trial.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Incidence of octreotide SC depot-related AEs and SAEs during 2 years of treatment. Focus is on related AESIs and Other Safety Information.
기간: From enrollment to the end of treatment at 2 years
|
From enrollment to the end of treatment at 2 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in absolute IGF-1 levels and relative IGF-1 (IGF-1/ULN) over time.
기간: From enrollment to the end of treatment at 2 years
|
From enrollment to the end of treatment at 2 years
|
|
|
Change in proportion of participants with IGF-1 ≤1×ULN over time.
기간: From enrollment to the end of treatment at 2 years
|
From enrollment to the end of treatment at 2 years
|
|
|
Change in GH levels over time.
기간: From enrollment to the end of treatment at 2 years
|
From enrollment to the end of treatment at 2 years
|
|
|
Change in proportion of participants with GH levels <1.0 μg/L over time.
기간: From enrollment to the end of treatment at 2 years
|
From enrollment to the end of treatment at 2 years
|
|
|
Incidence of octreotide SC depot non-related AEs and incidence of laboratory abnormalities using the CTCAE grading scale.
기간: From enrollment to the end of treatment at 2 years
|
From enrollment to the end of treatment at 2 years
|
|
|
Changes in symptoms of acromegaly over time, as measured by the Acromegaly Index of Severity (AIS) scale.
기간: From enrollment to the end of treatment at 2 years
|
The clinician-reported AIS Overall Score ranges from 0 to 18, where a higher score indicates more severe symptoms. |
From enrollment to the end of treatment at 2 years
|
|
Changes in QoL over time, as measured by the Acromegaly Quality of Life Questionnaire (AcroQoL).
기간: From enrollment to the end of treatment at 2 years
|
The AcroQoL domain scores range from 0 to 100, where a higher score indicates better quality of life. |
From enrollment to the end of treatment at 2 years
|
|
Changes in QoL over time, as measured by the Treatment Satisfaction Questionnaire for Medication (TSQM).
기간: From enrollment to the end of treatment at 2 years
|
The TSQM domain scores range from 0 to 100, where a higher score indicates greater treatment satisfaction. |
From enrollment to the end of treatment at 2 years
|
|
Changes in QoL over time, as measured by the Assessment of Acromegaly Symptoms (AAS) questionnaire.
기간: From enrollment to the end of treatment at 2 years
|
The patient-reported AAS total score ranges from 0 to 48, where a higher score indicates more severe symptoms. |
From enrollment to the end of treatment at 2 years
|
공동 작업자 및 조사자
스폰서
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .